SCHEMBL1009161

SCHEMBL1009161

Cc1cccc(C)c1COc1cc(CO)ccc1F

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC22A12 Q96S37 3/20 0.53
CYP4F2 P78329 1/20 0.50
CYP4A11 Q02928 1/20 0.50
MRGPRX4 Q96LA9 5/20 0.40
HTR6 P50406 1/20 0.38
RAB9A P51151 3/20 0.37
NPC1 O15118 2/20 0.37
CYP1A2 P05177 1/20 0.37
CYP3A4 P08684 1/20 0.37
CYP2D6 P10635 1/20 0.37
CYP2C9 P11712 1/20 0.37
CYP2C19 P33261 1/20 0.37
POLB P06746 1/20 0.37
PPARA Q07869 1/20 0.36
TP53 P04637 1/20 0.36
MAPT P10636 1/20 0.36
XBP1 P17861 1/20 0.36
HTT P42858 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
HSD17B10 Q99714 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13568832 0.87 SLC22A12 (0.51) SLC22A12CYP4F2CYP4A11MRGPRX4HTR6
SCHEMBL1062655 0.85 SLC22A12 (0.50) SLC22A12CYP4F2CYP4A11MRGPRX4HTR6
SCHEMBL956632 0.83 SLC22A12 (0.78) SLC22A12MRGPRX4RXRARXRBRXRG
SCHEMBL1235271 0.82 SLC22A12 (0.59) SLC22A12MRGPRX4RAB9ANPC1POLB
SCHEMBL1008012 0.82 SLC22A12 (0.50) SLC22A12MRGPRX4HTR6RAB9ANPC1
SCHEMBL3168485 0.78 CYP4F2 (0.51) CYP4F2CYP4A11MRGPRX4RAB9ANPC1
SCHEMBL459191 0.77 MRGPRX4 (0.55) SLC22A12MRGPRX4PPARARXRARXRB
SCHEMBL31215374 0.77 MRGPRX4 (0.55) SLC22A12MRGPRX4PPARARXRARXRB
SCHEMBL15779342 0.76 CYP4F2 (0.53) CYP4F2CYP4A11MRGPRX4RAB9ANPC1
SCHEMBL16957688 0.76 CYP4F2 (0.60) CYP4F2CYP4A11POLBMAPTHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3517109-A1 COMPOUNDS AND METHOD FOR REDUCING URIC ACID Wellstat Therapeutics Corporation (US) 2019-07-31 EP disclosed
EP-2268141-B1 COMPOUND AND METHOD FOR REDUCING URIC ACID WELLSTAT THERAPEUTICS CORP (US) 2019-05-08 EP disclosed
US-9115072-B2 Compounds and method for reducing uric acid WELLSTAT THERAPEUTICS CORPORATION (US) 2015-08-25 US disclosed
US-20130259850-A1 COMPOUNDS AND METHOD FOR REDUCING URIC ACID WELLSTAT THERAPEUTICS CORPORATION (US) 2013-10-03 US disclosed
EP-2268141-A1 COMPOUNDS AND METHOD FOR REDUCING URIC ACID Wellstat Therapeutics Corporation (US) 2011-01-05 EP disclosed
WO-2009151695-A1 COMPOUNDS AND METHOD FOR REDUCING URIC ACID WELLSTAT THERAPEUTICS CORPORATION (US) 2009-12-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130259850-A1 COMPOUNDS AND METHOD FOR REDUCING URIC ACID RCC2, HAX1, SLC10A6 SLC22A12 139/4885CYP4F2 392/4885CYP4A11 405/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.